Recent advances in immunotherapies for oncology hold great promise in areas of high unmet medical needs. From our Drug Discovery Center in San Diego, we are deploying our AI Drug Discovery Platform to develop a robust immuno-oncology pipeline. IBIO-101, an IL-2 sparing anti-CD25 antibody, has demonstrated strong anti-tumor responses in pre-clinical models of disease, and we anticipate filing an investigational new drug application for this candidate.
We have seven other immuno-oncology candidates in our pipeline, along with a PD-1 agonistic mAb intended to treat serious autoimmune disorders.
